Challenges in Molecular Monitoring for CML Treatment Response

Video

This video examines the challenge in optimizing and standardizing molecular monitoring for patients with chronic myeloid leukemia.

The success of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) has brought about the need to improve molecular monitoring in this patient population.

In this video, Susan Branford, MD, of the Centre for Cancer Biology and University of Adelaide, Australia, discusses some of the challenges in optimizing and standardizing molecular monitoring to an international reporting scale.

Branford highlights the potential need to move away from molecular milestones at 3, 6, and 12 months of TKI therapy and the variability among molecular assays that present a challenge in assessing response.

Recent Videos
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Related Content